Granulocyte colony-stimulating factor (G-CSF) is widely used to accelerate neutrophil recovery after allogeneic BMT or PBSC transplantation. The optimal time to start G-CSF treatment is not known. Forty-two patients undergoing allogeneic BMT or PBSC transplantation for hematological malignancies received G-CSF either on day 6 or on day 9 post transplant. The time to hematological recovery was monitored and the two groups were compared with respect to peritransplant morbidity and mortality. Recovery of the neutrophil counts to Ͼ0.1 ؋ 10 9 /l, Ͼ 0.5 ؋ 10 9 /l and Ͼ1.0 ؋ 10 9 /l were not significantly different in either group. There was no difference in recovery of red blood cell and platelet counts and no difference between the two groups with respect to the number of febrile days or number of days on antibiotic treatment. Documented bacterial, viral or fungal infections did not occur more often when G-CSF treatment was started on day 9. Delaying treatment with G-CSF resulted in a significant reduction in the length of treatment from 13 to 10 days (23.1% reduction). Reducing the length of the treatment by 3 days lowered the costs by 395.40 Euro per patient. Delaying G-CSF treatment and starting on day 9 after BMT or PBSC transplantation is safe and results in a clear economic benefit.
a significantly shorter time to an absolute neutrophil count Ͼ0.5 ϫ 10 9 /l in the treatment group. [1] [2] [3] These results were confirmed in a randomized, placebo controlled trial which demonstrated a 6-day reduction in the time for neutrophil recovery. 4 No adverse effects on the rate of acute GVHD or relapse rate have been reported so far. However, the optimal time to start G-CSF after allogeneic bone marrow transplantation is not clear. Several randomized studies have addressed this issue. [5] [6] [7] The study by Torres-Gomez et al 7 found no significant difference in neutrophil recovery and infectious complications in patients who started to receive G-CSF either on day 0 or day 7 post BMT. Similarly, a study from our own group showed that delaying treatment with G-CSF from day 1 to day 6 post BMT reduced treatment time and costs without an adverse effect on hematological recovery or rate of infectious complications. 5 These results were confirmed by an additional study which compared the start of treatment with G-CSF on day 0 to a start on day 5. 6 Interestingly, in this study the early mortality (at day 100) was significantly higher in the group receiving G-CSF on day 0. This increased mortality was in part accounted for by a higher frequency of veno-occlusive disease of the liver. This observation and other concerns make it seem advisable to reduce the duration of G-CSF treatment without compromising its beneficial effect on hematological recovery. In the present prospective study we report our experience with delaying the start of G-CSF treatment even further to day 9 post transplant. Since our previous study showed no difference between starting G-CSF on day 1 or day 6, a group of patients in which G-CSF was commenced on day 6 was used for comparison.
Patients and methods

Study population
From September 1999 to April 2001, 57 patients underwent allogeneic BMT or PBSC transplantation in our transplant unit. Only patients with hematological malignancies and conventional conditioning were included in the study. Three patients suffering from severe aplastic anemia were not included. Nine patients were excluded because a reduced intensity (mini-transplant) conditioning regimen had been chosen and administration of G-CSF was believed not to be necessary. One patient was excluded because of previous allergic reaction to G-CSF. The remaining 44 patients received G-CSF alternately either on day 6 (group A) or on day 9 (group B). Two patients dropped out of the study because they accidentally received G-CSF on day 1 or 3. The demographic characteristics of the two groups are summarized in Table 1 . The average age, sex, diagnosis and pretransplantation characteristics were comparable in both groups (Table 1) .
Nineteen patients had AML; eighteen were in first complete remission and one was in third relapse. Of the two patients with acute lymphatic leukemia (ALL), one was transplanted in first CR and one in second CR. One of the patients with CML in each group were transplanted in accelerated phase. One patient in group A was in blast crisis. The remaining patients with CML (n = 7 in group A and n = 8 in group B) were transplanted in first chronic phase. Two patients in group A and one patient in group B had myelodysplastic syndrome.
Fourteen patients in group A and 16 in group B were transplanted with HLA-identical siblings. HLA-identical, unrelated transplantation was performed in four patients in group A and in one in group B. A single mismatch was present in four patients in group A and in three in group B. AB0-compatibility was comparable in both groups. Ten patients in group A and 11 in group B were seropositive Table 1 Demographic characteristics of patients treated with G-CSF starting on day 6 (group A) or day 9 (group B) post transplant for CMV. One out of 12 seronegative patients in group A and two out of nine in group B received a seropositive allograft.
Group
Transplantation protocols
All conditioning regimens included cyclophosphamide at a standard total dose of 120 mg/kg body weight. In 16 patients it was combined with fractionated total body irradiation (TBI, 12 Gy in related donors, 13.2 Gy in unrelated donors). In 14 patients cyclophosphamide was combined with busulfan at a total dose of 16 mg/kg body weight. In four patients in group A and one in group B, cyclophosphamide and TBI were combined with ATG-Fresenius at a total dose of 30 mg/kg body weight. In one patient cyclophosphamide and busulfan were combined with ATG Fresenius at a total dose of 30 mg/kg body weight. In three patients VP-16 was added at a total dose of 20-60 mg/kg to cyclophosphamide and TBI (Table 1) . A total of 29 patients received BMT and 13 patients received PBSC transplantation.
G-CSF study protocol
All patients received a daily standard dose of 263 g of glycosylated lenograstim subcutaneously (Granocyte; Aventis Pharma, Zurich, Switzerland), either starting on day 6 (group A) or day 9 (group B). Patients were treated continuously until they reached neutrophil counts Ͼ1.0 ϫ 10 9 /l for 3 consecutive days.
Supportive care
All patients received graft-versus-host disease prophylaxis with short-course methotrexate (15 mg/m 2 on day +1, 10 mg/m 2 on days +3, +6 and +11) combined with cyclosporin A (starting with 10 mg/kg/day, continuous infusion, on day Ϫ1 to +21, followed by oral doses for 3 to 6 months. All patients received intravenous immunoglobulin 0.5 mg/kg weekly until day 40 after transplantation. All patients received leukocyte-depleted platelets and erythrocytes as required. All blood products were irradiated to 3000 cGy. For P. carinii prophylaxis trimethoprim/sulfamethoxazole was administered. Apart from this, no systemic prophylactic antibiotic, antiviral or antifungal treatment was given. Empirical antibiotic treatment was started as soon as the axillary body temperature rose above 38.0°C. Patients who did not respond to broad-spectrum antibiotics within 3 days received empiric antifungal treatment with amphotericin B. One patient in group A presented with suspected hepatosplenic candidiasis on a CT scan prior to BMT. Two patients in group B and four patients in group A had suspected pulmonary aspergillosis prior to transplantation. All of these patients were treated with fluconazole or itraconazole prior to and after transplantation. When neutrophil (PMN) counts dropped below 500/l fluconazole was replaced by amphotericin B.
All patients were treated in reverse isolation in HEPAfiltered laminar airflow single rooms. The first 12 patients (six in each group) received vancomycin, gentamycin and amphothericin orally for gut decontamination. In the following 30 patients, vancomycin was replaced by metronidazole.
Statistical analysis
Unpaired data were compared using the Mann-Whitney U test. Comparison of proportions was done using Fisher's exact test. Survival data were analyzed with a KaplanMeier curve and compared using the log-rank test.
Results
Hematological recovery
Bone marrow engraftment was achieved in all patients. Table 2 shows the hematological recovery of patients in group A and B. There was no statistical difference in PMN recovery between group A and group B. Subgroup analysis showed that patients in group A receiving BMT required 16.07 Ϯ 2.81 days to PMN recovery Ͼ0.5 ϫ 10 9 /l, whereas the eight patients receiving PBSC transplantation required 14.00 Ϯ 3.38 days. Similarly, in group B there was faster neutrophil recovery in patients receiving PBSC transplantation compared to BMT (days to reach PMN Ͼ0.5 ϫ 10 9 /l: 13.40 Ϯ 2.30 vs 15.87 Ϯ 2.42 days). No difference in platelet or erythrocyte recovery was observed.
Bone Marrow Transplantation
Clinical parameters and infectious complications
The clinical parameters of both groups are summarized in Table 3 . Seven patients in group A (31.82%) and five in group B (25.00%) remained afebrile after transplantation. Nevertheless, five of these patients in group A and two patients in group B were treated with antibiotics, all because of localized soft tissue infections, mainly perianal (five patients). One patient suffered from soft tissue infection of the abdominal wall and one patient had paradontitis. The total number of days patients were treated with antibiotics was comparable in both groups. The four positive blood cultures in group A grew coagulase negative staphylococci in three cases and P. aeruginosa in one case. In group B, one S. aureus bacteriemia and one bacteriemia with coagulase negative staphylococci was observed.
Episodes of presumed invasive fungal infection requiring antifungal treatment were analyzed. Patients with known fungal disease prior to BMT or PBSC transplantation were excluded. Three patients in group A and one patient in group B were treated with amphothericin B. CMV reactivation or disease occurred in one patient of group A and in four patients of group B. In three of the four patients of group B CMV antigenemia (pp65) was diagnosed, one patient suffered from intestinal CMV infection. In one patient in group A CMV infection of the lungs was suspected.
Cumulative survival of patients of group A and B was not statistically significant ( Figure 1 ). During the study period, five deaths were observed in the 42 patients included; three patients in group A and two in group B. One patient in group A died of pulmonary alveolar hemorrhage on day 17. Since no autopsy was performed the etiology of the hemorrhage could not be specified. Another patient who had been transplanted in the third relapse died 3 months post transplant from relapse. The third patient in group A died 16 months after PBSC transplantation, 9 months after relapse had been diagnosed. One patient in group B died of extensive chronic graft-versus-host disease 12 months after BMT and one patient in this group died 7 months after PBSC transplantation, 4 months after early relapse had been diagnosed. Two additional non-fatal relapses were observed in group A.
Graft-versus-host disease
All patients received the same prophylactic treatment including short-course methotrexate and cyclosporin A. The incidence of acute GVHD was comparable in both groups (Table 3) . Four patients in each group (18.18% in group A, 20.00% in group B) experienced grade II to IV GVHD. One patient in each group suffered from higher grade disease, reaching stage IV in group A and stage III in group B. All patients with II-IV grade GVHD were treated with additional immunosuppression. There was no significant difference of the incidence of chronic GVHD in the two groups.
Use of G-CSF
The average treatment time for G-CSF for group A was 13 days compared to 10 days in group B. The reduction of Table 2 Hematological recovery of patients treated with G-CSF starting on day 6 (group A) or day 9 (group B) post transplant a One patient excluded in group A because of death 16 days after BMT (n = 21). b Two patients excluded in group A: one patient died 16 days after BMT and one patient suffered from pure red cell aplasia (n = 20).
Table 3
Clinical outcome of patients treated with G-CSF beginning on day 6 (group A) or day 9 (group B) post transplant 
Discussion
Post-transplant administration of G-CSF has been shown to be beneficial in the setting of autologous BMT with respect to PMN recovery, duration of fever, infectious complications, antibiotic use and hospitalization. A number of randomized studies have also shown a significant acceleration in PMN recovery with G-CSF treatment in the setting of allogeneic BMT, using bone marrow 4 or peripheral blood as a source of stem cells. 8 Although current recommendations include the use of G-CSF, the optimal time point of the initiation of G-CSF treatment post-transplant remains to be defined. 9 Postponing treatment with hematopoietic growth factors seems to bear no disadvantage in the setting of autologous BMT. 10, 11 Similarly, three studies comparing different schedules of delayed G-CSF administration after allogeneic BMT found no difference in terms of PMN recovery or other important clinical end points. [5] [6] [7] On the contrary, in one study early G-CSF treatment was associated with increased early mortality. Moreover, delayed G-CSF treatment results in significant cost savings. Extending our observation reported in an earlier study, we compared the hematological and clinical outcome in 42 patients undergoing BMT or PBSC transplantation who alternately received G-CSF either on day 6 or day 9 post transplant. Similar to previous results there was no significant effect in delaying G-CSF treatment for 3 additional days on hematopoietic engraftment, infectious complications, morbidity, mortality or length of hospital stay. The pretransplant conditioning regimens were very similar in both groups and all patients received the same standardized GVHD prophylaxis. Also, the number of patients receiving a transplant with a single HLA mismatch was similar in both groups. We did not separate the groups according to source of stem cells, although a faster PMN recovery has been reported after PBSC transplantation. 12 Detailed analysis of our patients showed a slightly faster recovery of neutrophil count in patients receiving PBSC transplant. However, patients receiving a PBSC transplant were more numerous in group A, therefore not confounding the results in favor of group B.
While no adverse effects of delaying G-CSF administration to day 9 post transplant were observed, a number of potential advantages of reduced duration of G-CSF administration necessary to enhance hematopoietic engraftment are conceivable. First, there is a clear economic benefit. The number of treatment days could be further reduced to 10 days, compared to 13 days for group A, and 19 days for the day 1 group in our previously published study. There was no prolongation of hospital stay or increased use of antibiotics which would offset these economic benefits. Second, recent studies have demonstrated an immunomodulatory effect of several cytokines on allograft cells. G-CSF has a suspected immunosuppressive effect on peripheral blood stem cell allografts, including the shifting of cytokine production towards a type-2 helper cell response. 13, 14 In addition, G-CSF has been shown to decrease the number of NK cell progenitors and NK cell function in apheresis products. 15 An immunosuppressive effect of G-CSF has also been described with postgraft administration in the setting of T cell-depleted allografting for haplotype-mismatched transplantation, 16 where study patients receiving G-CSF to accelerate engraftment had a long lasting type-2 helper cell immune reactivity pattern. This type-2 shift was not seen in an identically treated group of patients not receiving G-CSF post tranplant. Although this potentially negative effect of G-CSF administration on immune reconstitution might be particularly pronounced in T cell-depleted transplants, G-CSF might also exert its immunosuppressive effect in other transplant situations. This, in turn, could have negative effects on Bone Marrow Transplantation infectious disease complications or the graft-versus-leukemia reaction.
In summary, our study showed that delaying treatment with G-CSF to day 9 after allogeneic BMT or PBSC transplantation is safe and does not result in an increase of infectious complications. Furthermore, delayed treatment results in significant cost savings.
